Zimmer Biomet Targets 2027 Launch For Semi-Autonomous Orthopedic Robot After Monogram Acquisition (MedTech Insight)
Survey Reveals Gaps In Medtech Compliance Processes (MedTech Insight)
Environmental Group Questions FDA’s Stance On PFAS In Medical Devices (MedTech Insight)
Food & Nutrition
Danone targets consumers taking weight loss drugs with new drink (Reuters)
Albertsons outlines defense against growing ingredients costs (Food Dive)
Government, Regulatory & Legal
Exclusive: USPS blocks shipping of illicit vapes in boost for Big Tobacco (Reuters)
Trump’s firing of the Bureau of Labor Statistics commissioner puts crucial health data at risk (STAT)
CDC shaken after gunman attacks its headquarters (STAT)
Inside the research machine that helps UnitedHealth protect its Medicare profits (STAT)
Trump administration launches investigation into Harvard’s federally funded research patents (STAT)
As Novo Nordisk ramps up lawsuits over Wegovy copies, investors ask where is Hims? (Reuters)
Updated: HHS official tasked with MAHA relations fired amid hasty rollout of mRNA contract cuts (Endpoints)
Telehealth Abortions Are Centered in Poor States With Few Options, Study Finds (Bloomberg)
Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is published each week on Monday, Tuesday and Thursday.
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
Adam Fisher, the staff director of the Office of Pharmaceutical Quality in the Center for Drug Evaluation and Research (CDER) at the US Food and Drug Administration (FDA), reported that the agency has approved 17 pharmaceuticals that utilize continuous manufacturing in their production.
The European Medicines Agency (EMA), in partnership with the European Commission (EC) and the Heads of Medicines Agencies (HMA), has published the first quarterly report on the state of clinical trials conducted in the EU and the European Economic Area (EEA). The report is intended to shed light on the progress being made to attract more clinical trials to the region and increase access to new treatments as part of the targets set by the EU in 2025.
An official from the US Food and Drug Administration (FDA) on Monday presented three case studies demonstrating how sponsors effectively utilized real-world evidence (RWE) and real-world data (RWD) to secure approval for their products.